Tracazolate

In this article we are going to explore the topic of Tracazolate, which has captured the attention of various areas of study and has generated great interest both in the academic field and in society in general. Tracazolate has long been the subject of debate and discussion, and its relevance has become increasingly evident in recent years. This topic has aroused the interest of researchers, scientists, professionals and the general public, due to its impact on different aspects of daily life. Throughout this article, we will explore the different aspects related to Tracazolate, analyzing its implications, its history, its influence today and possible future scenarios around this topic.

Not to be confused with cartazolate.
Tracazolate
Clinical data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • Ethyl 4-(butylamino)-1-ethyl-6-methyl-1H-pyrazolopyridine-5-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.050.178 Edit this at Wikidata
Chemical and physical data
FormulaC16H24N4O2
Molar mass304.394 g·mol−1
3D model (JSmol)
  • O=C(OCC)c1c(c2c(nc1C)n(nc2)CC)NCCCC
  • InChI=1S/C16H24N4O2/c1-5-8-9-17-14-12-10-18-20(6-2)15(12)19-11(4)13(14)16(21)22-7-3/h10H,5-9H2,1-4H3,(H,17,19)
  • Key:PCTRYMLLRKWXGF-UHFFFAOYSA-N

Tracazolate (ICI-136,753) is an anxiolytic drug which is used in scientific research. It is a pyrazolopyridine derivative, most closely related to pyrazolopyrimidine drugs such as zaleplon, and is one of a structurally diverse group of drugs known as the nonbenzodiazepines which act at the same receptor targets as benzodiazepines but have distinct chemical structures.[1]

Tracazolate has primarily anxiolytic and anticonvulsant effects, with sedative and muscle relaxant effects only appearing at higher doses.[2] It has a unique receptor binding profile involving allosteric modulation of several GABAA receptor subtypes, being selective for GABAA receptors containing α1 and β3 subunits, but exhibiting different effects depending on the third type of subunit making up the receptor complex.[3]

See also

References

  1. ^ Patel JB, Malick JB, Salama AI, Goldberg ME (October 1985). "Pharmacology of pyrazolopyridines". Pharmacology, Biochemistry, and Behavior. 23 (4): 675–80. doi:10.1016/0091-3057(85)90436-8. PMID 2866547. S2CID 31584179.
  2. ^ Patel JB, Malick JB (March 1982). "Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent". European Journal of Pharmacology. 78 (3): 323–33. doi:10.1016/0014-2999(82)90034-6. PMID 6121711.
  3. ^ Thompson SA, Wingrove PB, Connelly L, Whiting PJ, Wafford KA (April 2002). "Tracazolate reveals a novel type of allosteric interaction with recombinant gamma-aminobutyric acid(A) receptors". Molecular Pharmacology. 61 (4): 861–9. doi:10.1124/mol.61.4.861. PMID 11901225. S2CID 7039885.